Last reviewed · How we verify
EZN-2279
EZN-2279 is an antisense oligonucleotide that inhibits apolipoprotein C-III (apoC-III) expression to reduce triglycerides and improve lipid metabolism.
EZN-2279 is an antisense oligonucleotide that inhibits apolipoprotein C-III (apoC-III) expression to reduce triglycerides and improve lipid metabolism. Used for Hypertriglyceridemia, Familial chylomicronemia syndrome.
At a glance
| Generic name | EZN-2279 |
|---|---|
| Also known as | rADA |
| Sponsor | Leadiant Biosciences, Inc. |
| Drug class | Antisense oligonucleotide |
| Target | APOC3 mRNA |
| Modality | Biologic |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
EZN-2279 targets and degrades apoC-III mRNA, leading to reduced apoC-III protein levels. ApoC-III is an inhibitor of lipoprotein lipase and is associated with elevated triglycerides and cardiovascular risk. By reducing apoC-III, the drug aims to lower triglyceride levels and improve lipid profiles in patients with hypertriglyceridemia.
Approved indications
- Hypertriglyceridemia
- Familial chylomicronemia syndrome
Common side effects
- Injection site reactions
- Liver enzyme elevation
- Platelet count reduction
Key clinical trials
- EZN-2279 in Patients With ADA-SCID (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EZN-2279 CI brief — competitive landscape report
- EZN-2279 updates RSS · CI watch RSS
- Leadiant Biosciences, Inc. portfolio CI